{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T10:30:17Z","timestamp":1788517817178,"version":"build-2803163510"},"reference-count":87,"publisher":"Georg Thieme Verlag KG","issue":"02","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hamostaseologie"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immune checkpoint inhibitors (ICIs) and chimeric antigen receptor (CAR) T cells are novel therapeutic strategies that enhance anticancer immunity by activating or engineering cancer-targeting T cells. The resulting hyperinflammation carries several side effects, ranging from autoimmune-like symptoms to cytokine release syndrome (CRS), with potentially severe consequences. Recent findings indicate that ICIs increase the risk of venous and arterial thromboembolic adverse events. Patients with prior VTE might be at higher risk of developing new events under ICI while other risk factors vary across studies. So far, data on CAR T-linked coagulopathies are limited. Hypofibrinogenemia in the presence of CRS is the most commonly observed dysregulation of hemostatic parameters. A rare but particularly severe adverse event is the development of disseminated intravascular coagulation activation, which can occur in the setting of CRS and may be linked to immune effector cell-associated hemophagocytic lymphohistiocytosis. While the increasing number of studies on thromboembolic complications and coagulation alterations under ICIs and CAR T therapies are concerning, these results might be influenced by the retrospective study design and the heterogeneous patient populations. Importantly, numerous promising new T cell-based immunotherapies are currently under investigation for various cancers and are expected to become very prominent therapy options in the near future. Therefore, coagulopathies and thrombosis under T cell-directed immuno- and anti-cancer therapies is important. Our review provides an overview of the current understanding of ICI- and CAR T-associated thromboembolism. We discuss pathogenic mechanisms of inflammation-associated coagulation activation and explore potential biomarkers for VTE.<\/jats:p>","DOI":"10.1055\/a-2528-5071","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T19:13:07Z","timestamp":1746645187000},"page":"175-187","source":"Crossref","is-referenced-by-count":6,"title":["Checkpoint Inhibitors, CAR T Cells, and the Hemostatic System: What Do We Know So Far?"],"prefix":"10.1055","volume":"45","author":[{"given":"Christina C.","family":"Rolling","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hematology and BMT with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Lewirt","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hematology and BMT with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Beitzen-Heineke","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hematology and BMT with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"},{"name":"Department of Medicine, New York University Grossman School of Medicine, New York, New York, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lennart","family":"Beckmann","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hematology and BMT with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Bokemeyer","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hematology and BMT with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried","family":"Alsdorf","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hematology and BMT with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minna","family":"Voigtlaender","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hematology and BMT with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Langer","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hematology and BMT with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,5,7]]},"reference":[{"issue":"10","key":"ref1","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1002\/cncr.23062","article-title":"Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients","volume":"110","author":"A A Khorana","year":"2007","journal-title":"Cancer"},{"issue":"06","key":"ref2","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jama.293.6.715","article-title":"Malignancies, prothrombotic mutations, and the risk of venous thrombosis","volume":"293","author":"J W Blom","year":"2005","journal-title":"JAMA"},{"issue":"14","key":"ref3","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: a population-based cohort study","volume":"137","author":"F I Mulder","year":"2021","journal-title":"Blood"},{"issue":"08","key":"ref4","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jacc.2017.06.047","article-title":"Risk of arterial thromboembolism in patients with cancer","volume":"70","author":"B B Navi","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"01","key":"ref5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41572-022-00336-y","article-title":"Cancer-associated venous thromboembolism","volume":"8","author":"A A Khorana","year":"2022","journal-title":"Nat Rev Dis Primers"},{"issue":"01","key":"ref6","doi-asserted-by":"crossref","first-page":"52","DOI":"10.5482\/HAMO-14-08-0037","article-title":"Pathophysiology of Trousseau's syndrome","volume":"35","author":"C Dicke","year":"2015","journal-title":"Hamostaseologie"},{"issue":"01","key":"ref7","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1182\/bloodadvances.2021005590","article-title":"The incidence of cancer-associated thrombosis is increasing over time","volume":"6","author":"A Mahajan","year":"2022","journal-title":"Blood Adv"},{"issue":"09","key":"ref8","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/s41569-021-00552-1","article-title":"Interplay between inflammation and thrombosis in cardiovascular pathology","volume":"18","author":"K Stark","year":"2021","journal-title":"Nat Rev Cardiol"},{"issue":"07","key":"ref9","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1046\/j.1538-7836.2003.00261.x","article-title":"Inflammation and thrombosis","volume":"1","author":"C T Esmon","year":"2003","journal-title":"J Thromb Haemost"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"A Ribas","year":"2018","journal-title":"Science"},{"issue":"04","key":"ref11","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"D M Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"03","key":"ref12","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the PD1 inhibitory pathway","volume":"18","author":"A H Sharpe","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"102536","DOI":"10.1016\/j.eclinm.2024.102536","article-title":"Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade-a worldwide perspective","volume":"70","author":"P Gougis","year":"2024","journal-title":"EClinicalMedicine"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"960398","DOI":"10.3389\/fcvm.2023.960398","article-title":"Platelet-monocyte aggregates: molecular mediators of thromboinflammation","volume":"10","author":"C C Rolling","year":"2023","journal-title":"Front Cardiovasc Med"},{"issue":"06","key":"ref15","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"M Norelli","year":"2018","journal-title":"Nat Med"},{"issue":"06","key":"ref16","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"T Giavridis","year":"2018","journal-title":"Nat Med"},{"issue":"10","key":"ref17","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1007\/s00262-023-03490-8","article-title":"Chimeric antigen receptor macrophages activated through TLR4 or IFN-\u03b3 receptors suppress breast cancer growth by targeting VEGFR2","volume":"72","author":"Z Duan","year":"2023","journal-title":"Cancer Immunol Immunother"},{"issue":"01","key":"ref18","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.molimm.2015.03.244","article-title":"Complement and platelets: mutual interference in the immune network","volume":"67","author":"C Speth","year":"2015","journal-title":"Mol Immunol"},{"issue":"02","key":"ref19","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1055\/s-0038-1648857","article-title":"Platelet activation induced by interleukin-6: evidence for a mechanism involving arachidonic acid metabolism","volume":"72","author":"L Oleksowicz","year":"1994","journal-title":"Thromb Haemost"},{"issue":"04","key":"ref20","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1182\/blood-2002-02-0620","article-title":"Platelet activation induced by human antibodies to interleukin-8","volume":"101","author":"V Regnault","year":"2003","journal-title":"Blood"},{"issue":"06","key":"ref21","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1182\/blood-2005-03-1247","article-title":"Tumor necrosis factor-alpha as trigger of platelet activation in patients with heart failure","volume":"106","author":"P Pignatelli","year":"2005","journal-title":"Blood"},{"issue":"01","key":"ref22","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1182\/blood.V86.1.250.bloodjournal861250","article-title":"Th1 and Th2 T-helper cells exert opposite regulatory effects on procoagulant activity and tissue factor production by human monocytes","volume":"86","author":"G Del Prete","year":"1995","journal-title":"Blood"},{"issue":"01","key":"ref23","first-page":"8393","article-title":"Tissue factor (TF) is upregulated in tumor-bearing mice treated with immune checkpoint inhibitor (ICI)","volume":"140","author":"Y J Shim","year":"2022","journal-title":"The American Society of Hematolgy"},{"issue":"01","key":"ref24","first-page":"8365","article-title":"Immune checkpoint inhibitors (ICI) promote neutrophil-platelet aggregate and NET formation in tumor-bearing mice","volume":"140","author":"Y J Shim","year":"2022","journal-title":"The American Society Hematology"},{"issue":"10","key":"ref25","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1182\/blood.2020007008","article-title":"Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome","volume":"136","author":"E A Middleton","year":"2020","journal-title":"Blood"},{"issue":"02","key":"ref26","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1084\/jem.178.2.669","article-title":"CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40","volume":"178","author":"M R Alderson","year":"1993","journal-title":"J Exp Med"},{"issue":"04","key":"ref27","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.tcm.2007.02.004","article-title":"CD40 and its ligand in atherosclerosis","volume":"17","author":"E Lutgens","year":"2007","journal-title":"Trends Cardiovasc Med"},{"issue":"10","key":"ref28","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1038\/s41591-019-0590-4","article-title":"Single-cell immune landscape of human atherosclerotic plaques","volume":"25","author":"D M Fernandez","year":"2019","journal-title":"Nat Med"},{"issue":"11","key":"ref29","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1161\/CIRCRESAHA.120.316770","article-title":"Microanatomy of the human atherosclerotic plaque by single-cell transcriptomics","volume":"127","author":"M AC Depuydt","year":"2020","journal-title":"Circ Res"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejca.2021.09.010","article-title":"Immune checkpoint inhibitors for cancer and venous thromboembolic events","volume":"158","author":"J Gong","year":"2021","journal-title":"Eur J Cancer"},{"issue":"05","key":"ref31","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1161\/ATVBAHA.111.224709","article-title":"Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation","volume":"31","author":"D X Bu","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"09","key":"ref32","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.3390\/cells9091987","article-title":"Antibody-mediated inhibition of CTLA4 aggravates atherosclerotic plaque inflammation and progression in hyperlipidemic mice","volume":"9","author":"K Poels","year":"2020","journal-title":"Cells"},{"issue":"04","key":"ref33","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jaccao.2020.08.007","article-title":"Immune checkpoint inhibitor therapy aggravates T cell-driven plaque inflammation in atherosclerosis","volume":"2","author":"K Poels","year":"2020","journal-title":"JACC Cardiooncol"},{"issue":"06","key":"ref34","doi-asserted-by":"crossref","first-page":"e002916","DOI":"10.1136\/jitc-2021-002916","article-title":"Immune checkpoint inhibitor treatment and atherosclerotic cardiovascular disease: an emerging clinical problem","volume":"9","author":"K Poels","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"12","key":"ref35","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1182\/blood.2020007878","article-title":"Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy","volume":"137","author":"F Moik","year":"2021","journal-title":"Blood"},{"issue":"01","key":"ref36","doi-asserted-by":"crossref","first-page":"e001719","DOI":"10.1136\/jitc-2020-001719","article-title":"Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival","volume":"9","author":"T A Sussman","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"06","key":"ref37","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s11523-021-00852-z","article-title":"Thromboembolism in patients with metastatic renal cell carcinoma treated with immunotherapy","volume":"16","author":"I Y Sheng","year":"2021","journal-title":"Target Oncol"},{"issue":"05","key":"ref38","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s11523-022-00905-x","article-title":"Thromboembolism in patients with metastatic urothelial cancer treated with immune checkpoint inhibitors","volume":"17","author":"I Y Sheng","year":"2022","journal-title":"Target Oncol"},{"issue":"02","key":"ref39","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s11239-022-02649-x","article-title":"Incidence of venous thromboembolism and discriminating capacity of Khorana score in lung cancer patients treated with immune checkpoint inhibitors","volume":"54","author":"S Alma","year":"2022","journal-title":"J Thromb Thrombolysis"},{"issue":"04","key":"ref40","first-page":"423","article-title":"Increased Incidence of Venous Thromboembolism with Cancer Immunotherapy","volume":"2","author":"J Roopkumar","year":"2021","journal-title":"Med (N Y)"},{"issue":"03","key":"ref41","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s11239-023-02860-4","article-title":"COMPASS-CAT versus Khorana risk assessment model for predicting venous thromboembolic events in patients with non-small cell lung cancer on active treatment with chemotherapy and\/or immunotherapy, the CK-RAM study","volume":"56","author":"H Abdel-Razeq","year":"2023","journal-title":"J Thromb Thrombolysis"},{"issue":"10","key":"ref42","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1007\/s12094-022-02860-5","article-title":"Immune checkpoint inhibitors-associated thrombosis in patients with lung cancer and melanoma: a study of the Spanish society of medical oncology (SEOM) thrombosis and cancer group","volume":"24","author":"M S C\u00e1novas","year":"2022","journal-title":"Clin Transl Oncol"},{"issue":"04","key":"ref43","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1007\/s10637-019-00881-6","article-title":"Risk factors for cancer-associated thrombosis in patients undergoing treatment with immune checkpoint inhibitors","volume":"38","author":"Y Ando","year":"2020","journal-title":"Invest New Drugs"},{"issue":"11","key":"ref44","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1055\/s-0043-1769609","article-title":"Risk factors of venous thromboembolic disease in cancer patients treated with immune checkpoint inhibitor","volume":"123","author":"J D le S\u00e8ve","year":"2023","journal-title":"Thromb Haemost"},{"issue":"05","key":"ref45","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1111\/jth.15272","article-title":"Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors","volume":"19","author":"O Icht","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"12","key":"ref46","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1080\/17474086.2023.2276209","article-title":"Evaluating the effect of immune checkpoint inhibitors on venous thromboembolism in non-small cell lung cancer patients","volume":"16","author":"X He","year":"2023","journal-title":"Expert Rev Hematol"},{"issue":"12","key":"ref47","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1111\/jth.15883","article-title":"The Khorana score and venous and arterial thrombosis in patients with cancer treated with immune checkpoint inhibitors: a Danish cohort study","volume":"20","author":"T F Overvad","year":"2022","journal-title":"J Thromb Haemost"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.thromres.2020.09.038","article-title":"Venous and arterial thromboembolic events with immune checkpoint inhibitors: a systematic review","volume":"196","author":"C Solinas","year":"2020","journal-title":"Thromb Res"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.thromres.2021.02.028","article-title":"Letter to the editors-in-chief reply to: Solinas et al. Venous and arterial thromboembolic events with immune check point inhibitors: a systematic review","volume":"208","author":"C Frere","year":"2021","journal-title":"Thromb Res"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejca.2019.06.021","article-title":"Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective study","volume":"120","author":"J Bar","year":"2019","journal-title":"Eur J Cancer"},{"issue":"02","key":"ref51","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jaccao.2019.11.013","article-title":"Immune checkpoint inhibitor-related adverse cardiovascular events in patients with lung cancer","volume":"1","author":"K R Chitturi","year":"2019","journal-title":"JACC Cardiooncol"},{"issue":"48","key":"ref52","doi-asserted-by":"crossref","first-page":"4964","DOI":"10.1093\/eurheartj\/ehab618","article-title":"Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis","volume":"42","author":"C Dolladille","year":"2021","journal-title":"Eur Heart J"},{"issue":"24","key":"ref53","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","article-title":"Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque","volume":"142","author":"Z D Drobni","year":"2020","journal-title":"Circulation"},{"issue":"24","key":"ref54","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1161\/CIRCULATIONAHA.120.048708","article-title":"Immune checkpoint inhibitor therapy induces inflammatory activity in large arteries","volume":"142","author":"R Calabretta","year":"2020","journal-title":"Circulation"},{"issue":"10","key":"ref55","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"A A Khorana","year":"2008","journal-title":"Blood"},{"issue":"11","key":"ref56","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1007\/s00262-023-03508-1","article-title":"Thrombotic risk of platinum combination chemotherapy with and without immune checkpoint inhibitors for advanced non-small cell lung cancer: a nationwide inpatient database study","volume":"72","author":"C Iwai","year":"2023","journal-title":"Cancer Immunol Immunother"},{"issue":"16","key":"ref57","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.23.00294","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update","volume":"41","author":"N S Key","year":"2023","journal-title":"J Clin Oncol"},{"issue":"36","key":"ref58","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"B J Schneider","year":"2021","journal-title":"J Clin Oncol"},{"issue":"04","key":"ref59","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"R C Sterner","year":"2021","journal-title":"Blood Cancer J"},{"issue":"04","key":"ref60","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"D W Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"20","key":"ref61","first-page":"2430","article-title":"How I treat refractory CRS and ICANS after CAR T-cell therapy","volume":"141","author":"M D Jain","year":"2023","journal-title":"Blood"},{"issue":"05","key":"ref62","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.bbmt.2019.11.027","article-title":"Coagulation disorders after chimeric antigen receptor T cell therapy: analysis of 100 patients with relapsed and refractory hematologic malignancies","volume":"26","author":"Y Wang","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"07","key":"ref63","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s00277-019-03685-z","article-title":"Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy","volume":"98","author":"H Jiang","year":"2019","journal-title":"Ann Hematol"},{"issue":"12","key":"ref64","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1007\/s00277-023-05477-y","article-title":"IL-10 plus the EASIX score predict bleeding events after anti-CD19 CAR T-cell therapy","volume":"102","author":"X Wang","year":"2023","journal-title":"Ann Hematol"},{"issue":"02","key":"ref65","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1182\/bloodadvances.2020002757","article-title":"Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy","volume":"5","author":"J Buechner","year":"2021","journal-title":"Blood Adv"},{"issue":"01","key":"ref66","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/bjh.18596","article-title":"Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti-CD19 CAR-T cells","volume":"201","author":"E Galli","year":"2023","journal-title":"Br J Haematol"},{"issue":"21","key":"ref67","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1182\/bloodadvances.2021004716","article-title":"Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy","volume":"5","author":"A Johnsrud","year":"2021","journal-title":"Blood Adv"},{"issue":"07","key":"ref68","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/bloodadvances.2020004142","article-title":"Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy","volume":"6","author":"K R Juluri","year":"2022","journal-title":"Blood Adv"},{"issue":"18","key":"ref69","doi-asserted-by":"crossref","first-page":"5316","DOI":"10.1182\/bloodadvances.2023010336","article-title":"Real-world results of CAR T-cell therapy for large B-cell lymphoma with CNS involvement: a GLA\/DRST study","volume":"7","author":"F Ayuk","year":"2023","journal-title":"Blood Adv"},{"issue":"24","key":"ref70","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"K Rejeski","year":"2021","journal-title":"Blood"},{"issue":"07","key":"ref71","doi-asserted-by":"crossref","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"M R Hines","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"40","key":"ref72","doi-asserted-by":"crossref","first-page":"e1692","DOI":"10.1097\/MD.0000000000001692","article-title":"Coagulation disorders and bleedings in critically ill patients with hemophagocytic lymphohistiocytosis","volume":"94","author":"S Valade","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"08","key":"ref73","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.3324\/haematol.2022.281455","article-title":"Hemophagocytic lymphohistiocytosis and disseminated intravascular coagulation are underestimated, but fatal adverse events in chimeric antigen receptor T-cell therapy","volume":"108","author":"Z Song","year":"2023","journal-title":"Haematologica"},{"issue":"14","key":"ref74","first-page":"1639","article-title":"Chinese expert consensus on the management of chimeric antigen receptor T cell therapy-associated coagulopathy","volume":"135","author":"H Mei","year":"2022","journal-title":"Chin Med J (Engl)"},{"issue":"35","key":"ref75","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.21.01992","article-title":"Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline","volume":"39","author":"B D Santomasso","year":"2021","journal-title":"J Clin Oncol"},{"issue":"01","key":"ref76","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s40164-024-00573-9","article-title":"New insights into CAR T-cell hematological toxicities: manifestations, mechanisms, and effective management strategies","volume":"13","author":"Y Yang","year":"2024","journal-title":"Exp Hematol Oncol"},{"issue":"17","key":"ref77","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1182\/bloodadvances.2020002060","article-title":"Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma","volume":"4","author":"H Hashmi","year":"2020","journal-title":"Blood Adv"},{"issue":"04","key":"ref78","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1080\/10428194.2020.1852474","article-title":"Incidence, management and outcomes of arterial and venous thrombosis after chimeric antigen receptor modified T cells for B cell lymphoma and multiple myeloma","volume":"62","author":"A L Parks","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"06","key":"ref79","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1080\/10428194.2022.2030475","article-title":"Incidence of thrombosis in relapsed\/refractory B-cell lymphoma treated with axicabtagene ciloleucel: Mayo Clinic experience","volume":"63","author":"M Melody","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"09","key":"ref80","doi-asserted-by":"crossref","first-page":"8349","DOI":"10.3390\/ijms24098349","article-title":"Thrombotic events are unusual toxicities of chimeric antigen receptor T-cell therapies","volume":"24","author":"C Schorr","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"07","key":"ref81","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/j.jtha.2024.03.021","article-title":"A meta-analysis to assess the risk of bleeding and thrombosis following chimeric antigen receptor T-cell therapy: communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy","volume":"22","author":"P Bindal","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref82","doi-asserted-by":"crossref","first-page":"e006365","DOI":"10.1136\/jitc-2022-006365","article-title":"Characterization of the endotheliopathy, innate-immune activation and hemostatic imbalance underlying CAR-T cell toxicities: laboratory tools for an early and differential diagnosis","volume":"11","author":"A B Moreno-Casta\u00f1o","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"04","key":"ref83","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients","volume":"41","author":"M J Friedrich","year":"2023","journal-title":"Cancer Cell"},{"issue":"21","key":"ref84","doi-asserted-by":"crossref","first-page":"6737","DOI":"10.3390\/jcm12216737","article-title":"T-cell engaging antibodies in diffuse large B cell lymphoma - an update","volume":"12","author":"S Balendran","year":"2023","journal-title":"J Clin Med"},{"issue":"09","key":"ref85","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"H Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"07","key":"ref86","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies - BiTEs and beyond","volume":"17","author":"M E Goebeler","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"ref87","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1158\/1078-0432.CCR-22-1922","article-title":"Tumor-infiltrating lymphocyte therapy in melanoma: facts to the future","volume":"29","author":"A Betof Warner","year":"2023","journal-title":"Clin Cancer Res"}],"container-title":["H\u00e4mostaseologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2528-5071.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T19:13:57Z","timestamp":1746645237000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2528-5071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":87,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2025,5,4]]},"published-print":{"date-parts":[[2025,4]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2528-5071","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0720-9355","2567-5761"],"issn-type":[{"value":"0720-9355","type":"print"},{"value":"2567-5761","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]}}}